\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ decreased\\ color\\ perception\\ on\\ right\\.\ \(0\)\
\-\ \\â\\€\\¢\\ no\\ proptosis\\ or\\ chemosis\ \(0\)\
\-\ high\\ dose\\ steroid\\ treatment\\.\ \(0\)\
\-\ \\â\\€\\¢\\ hyperintense\\ optic\\ nerve\\ on\\ right\\ on\\ t2\\ sequences\\.\ \(0\)\
\-\ \\â\\€\\¢\\ focal\\ enhancement\\ posterior\\ intra\\-orbital\\ portion\\ of\\ right\\ optic\\ nerve\\.\ \(0\)\
\-\ \\â\\€\\¢\\ normal\\ left\\ optic\\ nerve\\.\ \(0\)\
\-\ \\â\\€\\¢\\ hyperintense\\ lesion\\ in\\ cervical\\ cord\\ seen\\ on\\ gradient\\ echo\\ sagittal\\ study\\.\ \(0\)\
\-\ \\â\\€\\¢\\ neg\\ brain\\ mri\\.\ \(0\)\
\-\ devic\\ disease\\ \\(optic\\ neuritis\\ \\&\\ spinal\\ cord\\ plaques\\)\ \(0\)\
\-\ \\â\\€\\¢\\ optic\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ neuromyelitis\\ optica\\ \\(devic\\ disease\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lyme\\ disease\ \(0\)\
\-\ 28\\ year\\ old\\ woman\\ presents\\ with\\ first\\ episode\\ of\\ right\\ eye\\ pain\\ and\\ decreased\\ vision\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.5016604260797571\ \(0\)\
\-\ devic\\:\\ 0\\.32789860726145476\ \(0\)\
\-\ nerve\\:\\ 0\\.2494491895657218\ \(0\)\
\-\ hyperintense\\:\\ 0\\.18542799281625158\ \(0\)\
\-\ cord\\:\\ 0\\.17279516901966546\ \(0\)\
\-\ neuromyelitis\\:\\ 0\\.16394930363072738\ \(0\)\
\-\ optica\\:\\ 0\\.16394930363072738\ \(0\)\
\-\ right\\:\\ 0\\.15457121354740117\ \(0\)\
\-\ perception\\:\\ 0\\.1497865033230419\ \(0\)\
\-\ chemosis\\:\\ 0\\.1497865033230419\ \(0\)\
\-\ disease\\:\\ 0\\.14677693869739775\ \(0\)\
\-\ decreased\\:\\ 0\\.14439311337069669\ \(0\)\
\-\ on\\:\\ 0\\.14080643643909574\ \(0\)\
\-\ neuritis\\:\\ 0\\.12974560979286895\ \(0\)\
\-\ lyme\\:\\ 0\\.12791460024070228\ \(0\)\
\-\ neg\\:\\ 0\\.12570351515975256\ \(0\)\
\-\ gradient\\:\\ 0\\.12233050636053228\ \(0\)\
\-\ proptosis\\:\\ 0\\.11759419629108786\ \(0\)\
\-\ plaques\\:\\ 0\\.11759419629108786\ \(0\)\
\-\ steroid\\:\\ 0\\.1123420960650242\ \(0\)\
\-\ dose\\:\\ 0\\.10884509190271628\ \(0\)\
\-\ echo\\:\\ 0\\.1079468109093313\ \(0\)\
\-\ episode\\:\\ 0\\.10666935735267606\ \(0\)\
\-\ color\\:\\ 0\\.10508156062204266\ \(0\)\
\-\ vision\\:\\ 0\\.10094664588103959\ \(0\)\
\-\ glioma\\:\\ 0\\.09901339531478734\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.09873156185658578\ \(0\)\
\-\ 28\\:\\ 0\\.09673329951431793\ \(0\)\
\-\ sequences\\:\\ 0\\.09324199999412679\ \(0\)\
\-\ eye\\:\\ 0\\.09324199999412679\ \(0\)\
\-\ sagittal\\:\\ 0\\.0896239542286174\ \(0\)\
\-\ cervical\\:\\ 0\\.08347876436917237\ \(0\)\
\-\ portion\\:\\ 0\\.08334651405783502\ \(0\)\
\-\ spinal\\:\\ 0\\.08276175740592014\ \(0\)\
\-\ first\\:\\ 0\\.07865571091537277\ \(0\)\
\-\ study\\:\\ 0\\.07773378302964305\ \(0\)\
\-\ brain\\:\\ 0\\.07266007603545296\ \(0\)\
\-\ focal\\:\\ 0\\.06971792984666007\ \(0\)\
\-\ enhancement\\:\\ 0\\.06708702611634418\ \(0\)\
\-\ t2\\:\\ 0\\.06705730596307663\ \(0\)\
\-\ high\\:\\ 0\\.06624222232302567\ \(0\)\
\-\ woman\\:\\ 0\\.06070222246235704\ \(0\)\
\-\ posterior\\:\\ 0\\.06027159320888175\ \(0\)\
\-\ mri\\:\\ 0\\.05982899247143146\ \(0\)\
\-\ presents\\:\\ 0\\.05606896890010487\ \(0\)\
\-\ lesion\\:\\ 0\\.05587905741932734\ \(0\)\
\-\ treatment\\:\\ 0\\.05552132870121012\ \(0\)\
\-\ seen\\:\\ 0\\.054873147900170643\ \(0\)\
\-\ normal\\:\\ 0\\.04758862290542491\ \(0\)\
\-\ of\\:\\ 0\\.045618593230067485\ \(0\)\
\-\ pain\\:\\ 0\\.04170766657051509\ \(0\)\
\-\ or\\:\\ 0\\.040547407320955575\ \(0\)\
\-\ left\\:\\ 0\\.03975945084282268\ \(0\)\
\-\ no\\:\\ 0\\.037902358110727105\ \(0\)\
\-\ year\\:\\ 0\\.03591995467225813\ \(0\)\
\-\ old\\:\\ 0\\.034495590486246924\ \(0\)\
\-\ in\\:\\ 0\\.02899510005475224\ \(0\)\
\-\ and\\:\\ 0\\.024084662729140775\ \(0\)\
\-\ with\\:\\ 0\\.02282292516432607\ \(0\)\
